Radiotherapy with cetuximab or durvalumab for advanced HNSCC
1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33 ...
Tag: head and neck squamous cell carcinoma
#VisualAbstract: Finotonlimab with chemotherapy increases overall survival in recurrent or metastatic head and neck cancer
Click here to read this study in Nature Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Ipsilateral radiotherapy has an increased risk for contralateral lymph node failure in ipsilateral tonsillar cancer
Click to read this study in JAMA Network Open.
#StudyGraphics: Concomitant chemoradiotherapy improves survival in elderly adults with locally advanced head and neck squamous cell carcinoma
Click to read this study in JAMA Network Open.
#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs cetuximab-chemotherapy in the PD-L1 positive population 2. While pembrolizumab-chemotherapy found an improved ...
#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
Click to read this study in JAMA Otolaryngology - Head & Neck Surgery.
#VisualAbstract: Tislelizumab significantly improves survival outcomes in advanced or metastatic esophageal squamous cell carcinoma
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Induction chemotherapy with erlotinib does not improve survival in stage III-IV head and neck squamous cell carcinoma
Click to read this study in Clinical Cancer Research.
#VisualAbstract: Pembrolizumab-based therapy is more effective with increasing PD-L1 expression in head and neck squamous cell carcinomas
Click to read this study in the Journal of Clinical Oncology.